Nonagen Bioscience Corporation is a clinical-stage diagnostics company advancing first-in-class, noninvasive tests for the detection and management of human cancers.
Our mission is to transform cancer care through high-performance, biomarker-driven diagnostics that enable earlier detection, more precise risk stratification, and better-informed clinical decision-making.
Our lead platform, Oncuria®, is a multiplex urine-based liquid biopsy that measures 10 validated protein biomarkers associated with bladder cancer. Built on over a decade of research and supported by more than $20 million in non-dilutive funding, Oncuria has been evaluated in over 5,000 patient samples across multiple international studies.
The Oncuria platform is designed to support three critical clinical use cases:
- Detection of urothelial cancer in patients with hematuria or suspected UTUC
- Monitoring for recurrence in patients with non–muscle invasive bladder cancer
- Prediction of response to intravesical Bacillus Calmette-Guérin (BCG) therapy
Oncuria has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for predicting response to BCG, underscoring its potential to address a significant unmet clinical need.
Nonagen has established a CAP-accredited, CLIA-certified laboratory in Irvine, California, and is actively launching its laboratory-developed tests (LDTs), with initial commercial partnerships and reimbursement pathways already in place.
By combining rigorous science, clinical validation, and scalable infrastructure, Nonagen is bringing precision diagnostics into everyday urologic practice—enabling clinicians to reduce unnecessary procedures, improve patient outcomes, and deliver more personalized cancer care.
Learn more: www.nonagenbioscience.com/products